[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco-smoking\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco-smoking":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,49,87,112,141,168,199,231,254,276,301,325,357,374,392,409,428,449,483,504,527,554,577,597,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100626897","efficacy-of-the-proactive-automatized-lifestyle-intervention-100626897",false,"NCT07441603","Efficacy of the Proactive Automatized Lifestyle Intervention","Investigating the Efficacy of the Proactive Automatized Lifestyle Intervention Among General Hospital Patients","ePAL","Inclusion Criteria:\n\n* Admitted to participating wards of the University Medicine Hospital Greifswald on Mondays through Thursdays\n\nExclusion Criteria:\n\n* cognitively or physically incapable\n* presence of a highly infectious disease\n* discharged or transferred within the first 24 hours\n* already recruited for study during previous stay\n* insufficient German language skills\n* employed the conducting research department\n* accompanying persons\n* no email address (and no phone number)","ALL","18 Years","64 Years",{"count":22,"type":23},788,"ESTIMATED","INTERVENTIONAL",[26],"NA","Background: Individual brief behavior change interventions often do not sufficiently address the common co-occurrence of multiple health risk behaviors among people. In addition, many interventions often fail to reach the majority of the target population and particularly those people who need them the most. To address these core challenges of individual prevention research, the \"Proactive Automatised Lifestyle intervention (PAL)\" was developed, a proactive screening and brief intervention driven by psychological health behavior change theory to motivate participants for behavior change. The trial ePAL aims to investigate the efficacy of the multi-behavior change intervention adressing tobacco smoking, alcohol use, diet and physical activity among general hospital patients over 2 years; and to investigate differential efficacy in different subgroups of patients.\n\nMethods: All patients admitted to non-intensive care wards on five medical departments within the University Medicine Hospital Greifswald (internal medicine A \\& B, surgery, trauma surgery, ear-nose-throat) and aged 18 to 64 years are systematically approached by study assistants and asked to first participate in a survey and then in the randomizd controlled trial, irrespective of their reason of admission. A total of 788 participants is allocated to two study groups. The intervention group receives individualized feedback on all four health risk behaviors to enhance motivation to change identified health risk behaviors. The feedback is driven by psychological behavior change theory, tailored to the participants' current stages of change and delivered after baseline and at months 1 and 3. The control group receives routine care and minimal assessment only. Follow-ups are conducted at months 6, 12 and 24 after baseline; and more are planned for. Efficacy will be measured concerning self-reported change in health risk behaviors, health and motivation to change measures using latent growth curve modelling.\n\nDiscussion: The trial will provide information on the efficacy of a population-based and individually tailored brief intervention to systematically provide individualized feedback to each patient for a healthy living. When found to be effective and implemented widely, such interventions may contribute to the prevention of widespread non-communicable diseases.",[29,30,31,32,33,34,35],"Health Risk Behaviors","Tobacco Smoking","Alcohol Use","Unhealthy Diet, Exercise, Smoking, and Alcohol Use","Unhealthy Diet","Insufficient Physical Activity","Vegetable Intake","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-25",{"date":44,"type":23},"2029-06",{"name":46,"class":47},"University Medicine Greifswald","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":48},"100557265","the-efficacy-of-conventional-screening-versus-mhealth-screening-in-early-detection-of-oral-potentially-malignant-disorders-and-oral-cancer-amongst-the-rural-population-of-varanasi-a-prospective-and-blinded-study-100557265","NCT06535867","The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study","Inclusion Criteria:\n\nPositive for any one or more of the following:\n\n* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and\u002For regular use of alcohol)\n* Clinical signs\u002Fsymptoms (non-healing ulcers, white\u002F red\u002Fred \\& white patches in the mouth, restriction of mouth opening and swelling of the neck)\n* All individuals aged above 40 irrespective of habit\u002Foral lesions\n\nExclusion Criteria:\n\n* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer\n* Under treatment for tuberculosis or suffering from any acute illness\u002F debilitating systemic disorders",true,{"count":57,"type":23},5122,"OBSERVATIONAL","Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India",[61,62,63,64,65,30,66,67],"Smoking","Smoking, Cigarette","Smoking, Tobacco","Betel Chewer's Mucosa","Tobacco Use","Alcohol Drinking","Smokeless Tobacco Hyperkeratosis",[69,70,71,72,73,74,75,76,77,78],"smoking","smoking, cigarette","smoking, tobacco","smokeless tobacco","betel leaf","areca nut","paan masala","alcohol use","Memorial Sloan Kettering Cancer Center","24-148","2026-05-19",{"date":81,"type":40},"2026-05-22",{"date":83,"type":40},"2024-07-30",{"date":85,"type":23},"2031-07-30",{"name":77,"class":47},{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":55,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100639243","abuse-liability-of-two-modern-oral-nicotine-pouched-products-100639243","NCT07595055","Abuse Liability of Two Modern Oral Nicotine Pouched Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) via dipstick at Screening and at Check-in Day 1.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.","21 Years","60 Years",{"count":97,"type":23},40,[26],"This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[61,101,65,30],"Smoking Behaviors","NOT_YET_RECRUITING","2026-05-12",{"date":79,"type":40},{"date":106,"type":23},"2026-06-15",{"date":108,"type":23},"2026-11-30",{"name":110,"class":111},"RAI Services Company","INDUSTRY",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":55,"sex":119,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":48},"100602905","trauma-informed-care-for-smoking-cessation-for-pregnancy-100602905","NCT07129590","Trauma-Informed Care for Smoking Cessation for Pregnancy","TRauma-Informed Care in Smoking cEssation for Pregnancy (RISE Pregnancy)","Inclusion Criteria:\n\nClinician Eligibility Criteria (Aims 1 - 3):\n\nIn Aims 1-3, will be recruiting clinicians working in our clinic sites.\n\n1. Nurse practitioner, physician assistant, nurse-midwife, medical doctor, registered nurse, clinical pharmacist, behavioral health professional, social worker, or any other healthcare professional caring for pregnant patient-participants.\n2. Age ≥ 18 years old.\n\nPatient-participant Eligibility Criteria (Aim 1):\n\nIn Aim 1, will be recruiting pregnant women (ages 18+) who:\n\n1. Currently smoking or report having smoked during a previous pregnancy\n2. Age ≥18 years old.\n3. Currently Pregnant.\n4. Identifies as a cisgender woman, or female at birth.\n5. Reports having experienced trauma aligned with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) definition for traumatic exposure.\n6. Proficient in English or Spanish languages.\n\nPatient-Participant Eligibility Criteria (Aim 2):\n\nPatient-participants will be recruited to give feedback on our intervention using Evidence-Based Quality Improvement (EBQI) meetings.\n\nInclusion criteria:\n\n1. Current or former patient in the participating clinical sites.\n2. Age ≥18 years old.\n3. Proficient in English or Spanish languages.\n\nPatient-Participant Eligibility Criteria (Aim 3): In Aim 3, will be recruiting pregnant women who are actively smoking and have histories of trauma (ages 18+).\n\nInclusion criteria:\n\n1. Currently smoking (ever smoked 100 cigarettes in their lifetime, smoked in the past 7 days and at least 1 cigarette per day, verified by CO≥6ppm)\n2. ≥18 years old\n3. Currently Pregnant\n4. Identifies as a cisgender women, or female at birth\n5. Meets DSM-5 Criterion A for trauma exposure on the Brief Trauma Questionnaire (BTQ)\n6. English or Spanish Proficient\n\nExclusion Criteria:\n\nClinician- and Patient-participant Exclusion criteria (Aims 1 - 3):\n\n1\\. Any condition, including active mental health crises or cognitive impairment, that would interfere with the ability to provide informed consent or safely complete the study.","FEMALE",{"count":121,"type":23},20,[26],"Trauma-informed approaches have been shown to support recovery from other substance use disorders and involve four key elements: (1) Realizing the prevalence of trauma and pathways to recovery, (2) Recognizing symptoms of trauma, (3) Responding by embedding knowledge of trauma into practices and policies and (4) Resisting re-traumatization (the 4Rs). In close partnership with Breathe California and a public safety-net clinic in San Francisco that serves primarily racial and ethnic minoritized (REM) pregnant women, the 4Rs along with the Ask, Advise, Assess, Assist and Arrange (the 5As) evidence-based intervention for tobacco cessation that is delivered by health care professionals and is a US Public Health Services clinical practice guideline for treating tobacco will be used to create and implement a smoking cessation intervention for pregnant women with experiences of trauma.",[125,30,126,127,62,128,129],"Smoking Cessation","Tobacco Use Cessation","Smoking Reduction","Trauma, Psychological","Trauma and Stressor Related Disorders",[131],"Pregnancy","2026-04-20",{"date":134,"type":40},"2026-04-23",{"date":136,"type":40},"2025-11-19",{"date":138,"type":23},"2026-07-31",{"name":140,"class":47},"University of California, San Francisco",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":24,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100532841","phase-2-cannabidiol-for-reducing-cigarette-use-100532841","NCT06218056","Cannabidiol for Reducing Cigarette Use","Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use","Inclusion Criteria:\n\nThe investigators will study equal numbers of males and females betweeen 18 - 65 years of age who have Tobacco Use Disorder and express a desire for smoking cessation. Participants will be recruited from the clientele base at Cri-Help Treatment Center in North Hollywood, CA, where the investigators have a long-standing relationship and where the investigators have conducted other research protocols. This study will be conducted at Cri-Help Treatment Center.\n\nParticipants will not be recruited from the general population for this study because common use of cannabis in the greater Los Angeles area would confound measurements of CBD, interfering with evaluation of the association of plasma level from treatment with efficacy. This problem is avoided in studying participants who are receiving treatment at a facility where cannabis use is not allowed.\n\nThe investigators will include all racial and ethnic groups. Based on the population of the surrounding communities in the Los Angeles region, the investigators anticipate a racial and ethnic makeup of approximately 26% White, 9% Black\u002FAfrican American, 49% Hispanic\u002FLatino, 14% Asian American, and 2% multi-racial\u002Funknown. These percentages align with our recent studies.\n\nSmoking cigarettes and at least moderate nicotine dependence, as indicated by smoking 5 or more cigarettes per day and\u002For a score of at least 4 on the Fagerström Test for Nicotine Dependence are inclusion criteria. Although vaping is popular and a high proportion of participants who vape also report cigarette smoking (58%), the investigators will exclude participants who vape nicotine. Vaping is not allowed at Cri-Help, Inc.\n\nExclusion Criteria:\n\n* Physiological dependence on alcohol or any drug, requiring medical detoxification and\u002For showing signs of acute withdrawal symptoms from opioids, alcohol or benzodiazepines.\n* Treatment of Opioid Use Disorder with buprenorphine or methadone to avoid potential drug-drug interactions. CBD interacts with CYP3A. Opioid drugs metabolized by cytochrome P450 (CYP450), and cytochrome P450 isoenzyme CYP3A4 (CYP3A4) in particular, include fentanyl, methadone, oxycodone, and buprenorphine.\n* Meeting DSM-5 criteria for schizophrenia, Bipolar I disorder, psychotic disorder, having active suicidal ideation, or suicide attempt in the past 12 months. NOTE: Participants with other psychiatric conditions, such as major depression, generalized anxiety, dysthymia, social phobia or specific phobia can enroll if they are clinically stable.\n* AIDS or current HIV medication treatment with antiviral and\u002For non-antiviral therapy (due to the interaction of CBD with antiviral therapy).\n* Clinically significant abnormalities on EKG (such as evidence of arrhythmia or MI).\n* Clinically significant cardiovascular, hematologic, hepatic, renal, neurological, or endocrine abnormalities \\[specific exclusion criteria: AST greater than or equal to 3Xs ULN, Bilirubin greater or equal to 1.5 X ULN, Prothrombin time\u002FInternational Normalized Ratio (INR) \\> 1.5.\n* Pregnancy and\u002For lactation. Contraception methods required at time of enrollment, and throughout the duration of the study medication period include abstinence, oral contraceptives, depot contraceptives, condom with spermicide, cervical cap with spermicide, diaphragm with spermicide, intrauterine device, surgical sterilization (e.g. tubal ligation, vasectomy).\n* Because of evidence that CBD affects ovarian function in rats, women with values outside the reference ranges on a hormonal battery \\[estradiol, follicle- stimulating hormone, free thyroxine index, luteinizing hormone, prolactin, total T3 and total T4, thyroid-stimulating hormone\\], followed by an abnormal ovarian ultrasound finding will be excluded.\n* Based on data obtained using Epidiolex® (CBD) oral solution label section 7, \"Drug Interactions\", the investigators will exclude participants who are taking the following medications: a) strong inducers of CYP3A4 or CYP2C19, which may decrease CBD plasma levels; and b) substrates of UGT1A9, UGT2B7, CYP2B6, CYP2C19 due to the potential of CBD to inhibit enzyme activity.","65 Years",{"count":150,"type":23},120,[152],"PHASE2","The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential.\n\nThe investigators will recruit participants from CRI-Help, Inc., a substance abuse treatment program in North Hollywood, where residents who indicate the desire to stop smoking are prohibited from using other cannabis products which would affect recruitment.\n\nThe aims of this study are:\n\n1. Evaluate the effects of CBD on nicotine intake.\n2. Exploratory Aims. Measure plasma concentrations of CBD, N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) at baseline and day 7.\n\nParticipants who meet eligibility criteria will take part in a 56-day treatment phase during which they receive the study medication under supervision (CBD or placebo twice daily) and complete questionnaires on side effects, withdrawal, craving and mood symptoms. Blood, breath, and urine tests will also be performed throughout the study. Participants who complete the treatment will also be assessed at 1-month and 3-month follow up visits.",[155,30,156],"Tobacco Use Disorder","Tobacco Dependence",[158,155,125],"Cannabidiol","2026-04-06",{"date":161,"type":40},"2026-04-13",{"date":163,"type":40},"2024-10-31",{"date":165,"type":23},"2026-12-31",{"name":167,"class":47},"University of California, Los Angeles",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100614044","smoking-harm-reduction-using-e-cigarettes-and-cytisine-100614044","NCT07274475","Smoking Harm Reduction Using E-cigarettes and Cytisine","Exploring Alternative Approaches to Harm Reduction and Cessation for Treatment-Resistant Tobacco Dependence","SHRECC","Inclusion Criteria:\n\n1. Willingness to comply with all study procedures, for the full duration of the study period (12 months);\n2. Age 18 years or older;\n3. Currently smoking 5 or more cigarettes daily; and\n4. Must have regular access to a phone and email to receive study communications and complete study monitoring.\n\nExclusion Criteria:\n\n1. Individuals who smoke only occasionally or have quit smoking prior to the 6-month follow-up;\n2. Daily or almost daily users of e-cigarettes for the past 30 days;\n3. Presence of medical or psychiatric conditions that may interfere with safe participation or compliance with the study protocol, including severe cardiovascular disorders, renal impairment or respiratory conditions;\n4. Known allergy or hypersensitivity to any components of the e-cigarettes, e-liquids, or cytisine;\n5. Pregnant or breastfeeding, or planning to become pregnant within the next 12 months; or\n6. Current use of pharmacological smoking cessation aids or participation in other smoking cessation clinical trials.",{"count":177,"type":23},6000,[26],"Smoking remains the leading cause of preventable death globally, with high prevalence in disadvantaged populations despite access to free nicotine replacement therapy (NRT) and counseling through Ontario's STOP Program. This study aims to evaluate the acceptability, feasibility, and comparative effectiveness of e-cigarettes and cytisine as harm-reduction tools for individuals who continue to smoke despite standard treatments. Over four years, 6,000 STOP participants who smoke ≥5 cigarettes daily at six months post-treatment will be randomized to receive either an e-cigarette starter kit or a 28-day cytisine supply. Data will be collected via REDCap and include biomarkers (NNAL, PAH), self-reported smoking behavior, nicotine dependence, and quality of life. Statistical analyses will assess changes and compare outcomes between groups. Results will inform public health strategies and enhance equitable cessation support for underserved populations.",[30,181,182],"Harm Reduction","Nicotine",[184,185,186,187,188,189],"Cytisine","E-cigarettes","Smoking cessation","treatment-resistant","Addiction","Clinical intervention","2026-03-17",{"date":192,"type":40},"2026-03-19",{"date":194,"type":23},"2026-05-01",{"date":196,"type":23},"2028-03",{"name":198,"class":47},"Centre for Addiction and Mental Health",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":119,"minAge":19,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":24,"phases":210,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":48},"100478851","phase-4-smoking-cessation-and-menstrual-cycle-phase-100478851","NCT05515354","Smoking Cessation and Menstrual Cycle Phase","Coordinating Smoking Cessation Treatment With Menstrual Cycle Phase to Improve Quit Outcomes: A Randomized Controlled Trial","MC-NRT","Inclusion Criteria:\n\n* Must provide informed consent following the CAMH REDCap e-consent framework and procedures;\n* Stated willingness to comply with all study procedures;\n* Naturally cycling individuals with regular MCs (defined as length ranging 21 to 35 days over past 6 months);\n* Daily smoker of ≥5 cigarettes per day (CPD) over past 6 months;\n* Intention to quit smoking within the next 30 days and willing to make a quit attempt on their assigned TQD;\n* Interested in using, and able to use, nicotine patches and gum or lozenge as a smoking cessation aid;\n* Willing to provide a valid e-mail address to be used for study communications and to complete online questionnaires.\n\nExclusion Criteria:\n\n* Current use of progesterone, estrogen, testosterone, or fertility treatment;\n* Current use of nicotine replacement therapy or other smoking cessation medications (e.g., varenicline, bupropion);\n* Use of hormonal contraceptives in the past 6 months (e.g., pill, patch, hormonal intrauterine device \\[IUD\\], ring);\n* Pregnancy, or trying to become pregnant in the next 2-3 months;\n* Known hypersensitivity or allergies to any of the components of the nicotine patch;\n* Daily or almost daily use of cannabis in the past 6 months;\n* Daily or almost daily use of tobacco or nicotine products other than cigarettes (e.g., smokeless tobacco, heat-not-burn products, e-cigarettes) in the past 6 months;\n* Polycystic ovary syndrome diagnosis;\n* Unstable psychiatric condition (including substance use disorder) which would compromise study compliance;\n* Life threatening arrhythmias or severe\u002Fworsening angina pectoris;\n* Myocardial infarction or cerebral vascular accident in the past 2 weeks; or\n* Diagnosed with a terminal illness.","40 Years",{"count":209,"type":23},1200,[211],"PHASE4","Tobacco use is a risk factor for at least 20 types of cancer and remains the leading preventable cause of cancer in Canada. Smoking cessation is an important cancer prevention strategy for the close to 2 million Canadian women who currently smoke. However, findings from controlled trials and real-world clinical settings indicate that women have greater difficulty achieving abstinence following a quit attempt than men. There is some evidence that hormonal levels and fluctuations throughout the menstrual cycle (MC) may contribute to the greater difficulty women experience when trying to quit smoking. In this study, the start of a quit attempt using nicotine replacement therapy (NRT) will be targeted to specific phases of MC. It was hypothesized that starting a quit attempt during the first half of MC (follicular phase) will result in increased quit success compared to starting during the second half of MC (luteal phase) or the usual practice of not targeting quit start date to MC phase.",[214,30,125,215,216],"Nicotine Dependence","Nicotine Use Disorder","Substance Use Disorders",[218,219,220,221,222,223,224,225],"Menstrual Cycle","Ovarian Hormones","Smoking Cessation Treatment","Nicotine Replacement Therapy","Cancer Prevention","Randomized Controlled Trial","Estrogen","Progesterone",{"date":192,"type":40},{"date":228,"type":40},"2022-11-30",{"date":165,"type":23},{"name":198,"class":47},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":48},"100623577","using-novel-behavioral-economic-measures-to-characterize-dual-marijuana-and-tobacco-use-in-young-adults-100623577","NCT07398443","Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults","MATEY","Inclusion Criteria:\n\n1. Males\u002Ffemales who are 18 to 25 years of age\n2. Young adults who currently smoke commercial tobacco cigarettes (≥1x weekly in the past 30 days and for the past six months)\n3. Young adults who currently smoke marijuana (≥4 times in past 30 days and at least weekly on average for the last six months)\n4. Participants must report purchasing their own tobacco and marijuana at least once in the past 6 months\n5. Participants must speak, comprehend, and read English.\n\nExclusion Criteria:\n\n1. Intention to quit marijuana or tobacco use in the next 30 days\n2. Self-reported illicit drug or heavy episodic alcohol use on \\>20 days in the past month (excluding marijuana)\n3. Individuals who are pregnant or breastfeeding\n4. Positive saliva test for recent THC use\n5. Breath alcohol level above 0 at any session.\n6. Participants who exclusively roll their own tobacco cigarettes","25 Years",{"count":150,"type":23},[26],"The multi session experimental study aims to determine dual use patterns of marijuana and tobacco by assessing the impact of price and availability of marijuana and tobacco using a cross price elasticity of demand task. The study will recruit 120 non-treatment seeking emerging young adults (18-25 years) who smoke marijuana and tobacco.",[243,244,30],"Behavioral Economics","Cannabis Smoking","2026-03-02",{"date":247,"type":40},"2026-03-04",{"date":249,"type":40},"2026-02-17",{"date":251,"type":23},"2028-11-30",{"name":253,"class":47},"Brown University",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":48},"100465208","app-for-pregnancy-smoking-cessation-with-peer-support-100465208","NCT05337722","App for Pregnancy Smoking Cessation With Peer Support","A Smartphone Intervention for Pregnancy Smoking Cessation With Peer Support","SFT","Inclusion Criteria:\n\n* age\\>=18\n* pregnant\n* user of regular cigarettes\n* availability of Android phone with broadband data\n\nExclusion Criteria:\n\n\\-",{"count":263,"type":23},790,[26],"The objectives of this project are to develop, implement, and test the feasibility and effectiveness of an artificial intelligence adaptive mobile pregnancy tobacco cessation app-based intervention using deep tailoring and a self-nominated support person, and to build mHealth research capacity in Romania. The central hypothesis is that the intervention will show evidence of feasibility and effectiveness in increasing positive support, pregnancy cessation, and postnatal abstinence. The intervention is grounded in Self-Determination Theory (SDT) and Motivational Interviewing (MI), a counselling style that is effective in assisting people to quit smoking. The app will be novel in its use of the unique functionality of smartphones, use of reinforcement learning (RL) and deep tailoring to continuously adapt the intervention, the emphasis on increasing positive support, and the use of the app by both smoker and support person. The long-term goal of the research program is to use mHealth for smoking cessation leveraging the unique functionality of smartphones and to continue building mHealth research capacity and developing research networks in Central and Eastern Europe (CEE) and other LMICs.\n\nAim 1 (R21 phase). Develop and test the feasibility and acceptability of the SFT2.0 app-based mobile smoking cessation intervention with a support person during pregnancy and postpartum in Romania. Through a user-centered and iterative design the investigators will enhance the SFT1.0 app, deepen the tailoring, incorporate RL, expand the app for use by any support person, and test the intervention including the app and MI video counseling in a series of usability studies and a 12-week open trial (n=20).\n\nAim 2 (R33 phase). Test the SFT2.0 app-based smoking cessation intervention in a hybrid effectiveness and implementation randomized controlled trial. The investigators will randomize 375 pregnant smokers and their support persons to i) a fixed arm, including the SFT2.0 app for both, and fixed pre- and postnatal MI counseling; ii) an RL-adaptive arm, with the app continuously optimizing as-needed MI counseling; or iii) control group.\n\nAim 3 (R21 and R33 phases). Develop mHealth research capacity by enhancing individual and institutional research capabilities in Romania and expanding the existing international research network.",[125,30],"2026-01-14",{"date":269,"type":40},"2026-01-16",{"date":271,"type":40},"2023-01-11",{"date":273,"type":23},"2026-08-31",{"name":275,"class":47},"Michigan State University",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100594502","connect-cancer-survivors-with-tobacco-treatment-100594502","NCT07020273","CONNECT Cancer Survivors With Tobacco Treatment","Cancer Prevention by Reducing Tobacco With Informatics and Chronic Care Approaches Trial (CONNECT)","Eligibility Criteria:\n\n* Be receiving care at a participating clinic\n* Report current tobacco use (assessed by the rooming staff during the index visit)\n* Have a completed appointment with a participating clinic\n* Be an adult (at least 18 years old).",{"count":284,"type":23},5000,[26],"The purpose of this study is to evaluate the comparative effectiveness of two different informatics-enabled implementation strategies on increasing tobacco treatment and improving smoking cessation rates for cancer control and prevention. This will be done via a two-arm pragmatic cluster randomized trial (CRT) to test the effectiveness of nudges to change (ELEVATE-S) vs. quit-focused usual care (ELEVATE) in increasing tobacco treatment (use of medication, brief advice, or referral to external counseling) and smoking cessation.",[65,126,125,288,30],"Nicotine Addiction",[290,291],"Patient Reported Outcomes","Tobacco Treatment","2026-01-06",{"date":294,"type":40},"2026-01-08",{"date":296,"type":40},"2025-07-01",{"date":298,"type":23},"2027-01-01",{"name":300,"class":47},"Washington University School of Medicine",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":307,"targetDuration":4,"studyType":24,"phases":309,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":48},"100473508","phase-1-oral-cannabidiol-for-tobacco-cessation-100473508","NCT05445804","Oral Cannabidiol for Tobacco Cessation","Inclusion Criteria:\n\n1. Have provided written informed consent\n2. Be between the ages of 18 and 65\n3. Report use of \\> 10 cigarettes per day for \\> 1 year with smoking status verified by either a positive breath carbon monoxide test (\\>8ppm) or urine cotinine test (\\>200ng\u002FmL) at screening\n4. Report interest in quitting tobacco in the next two months\n5. Are willing to engage in a series of practice quit attempts as part of the study.\n6. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests as determined by a licensed medical professional.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration. Acceptable forms of contraception include: double barrier contraception or a combination of a barrier contraception and a hormonal implant, injectable, combined oral contraceptive, or a male partner who has had a vasectomy; intrauterine device or tubal ligation.\n\nExclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders\n2. Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation\n3. Test positive for drugs of abuse (except nicotine) and\u002For breath alcohol test at study admission\n4. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity.\n5. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n6. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding.\n7. Use of an over the counter, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant\n8. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce\u002Finhibit CYP3A4 enzymes.\n9. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina).\n10. Have elevated serum liver transaminase (AST or ALT) above 2 x upper limit of normal, or elevated bilirubin above 1.5 x upper limit of normal.\n11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.\n\n    \\-",{"count":308,"type":23},50,[310],"PHASE1","Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.",[65,30,156,155,126],[314,61,158,315],"Tobacco","CBD","2026-01-05",{"date":318,"type":40},"2026-01-07",{"date":320,"type":40},"2022-11-01",{"date":322,"type":23},"2027-02-01",{"name":324,"class":47},"Johns Hopkins University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":48},"100595955","phase-3-intervention-to-increase-intention-to-change-alcoholtobacco-use-in-veterans-with-chronic-disease-100595955","NCT07039175","Intervention to Increase Intention to Change Alcohol\u002FTobacco Use in Veterans With Chronic Disease","A Low-Cost, High-Access Intervention to Increase Intention to Change Alcohol\u002FTobacco Use Among Reticent Veterans Who Are Non-Responders to Brief Advice at High Risk Due to Chronic Conditions","MINDSET","Inclusion Criteria:\n\n* an active diagnosis of diabetes, cardiovascular disease (CVD), or a cardiovascular risk factor (hypertension {HTN}, hyperlipidemia {HLD}) AND signs of reticence to change their smoking and\u002For alcohol use as evidenced by the two consecutive prior screens being positive for hazardous (e.g., Alcohol Use Disorders Test-Consumption \\[AUDC\\], and\u002For smoking (I.e., whether they are a current smoker or not).\n* Confirmation of smoking and\u002For drinking status during telephone screening (e.g., Alcohol Use Disorders Test-Consumption \\[AUDC\\], and\u002For smoking (I.e., whether they are a current smoker or not).\n* Veteran\n* Age 18 years\n* utilize VA for medical care more than 1 time per year\n* are due to complete their smoking\u002Falcohol use screen in approximately 3 months (to ensure they will likely receive UC during intervention period)\n* a scheduled PC appointment within the intervention period.\n\nExclusion Criteria:\n\n* dementia or severe cognitive impairment per Problem List\n* significant visual impairment per Problem List\n* Other Exclusion criteria assessed by study staff during screening\u002Fself-report are:\n\n  * inability to communicate or read in English;\n  * Hearing impairment; and\n  * cognitive impairment or screening for cognitive impairment (\\>=weighted score of 10 on Blessed screener).",{"count":334,"type":23},270,[336],"PHASE3","Many Veterans who have chronic conditions like cardiovascular disease or diabetes smoke or drink too much alcohol, which can worsen the condition. Veterans are asked yearly about drinking\u002Fsmoking and providers provide a brief advice discussion focused on behavior change. However, many Veterans continue to drink or smoke, and are often not interested in higher-intensity, change-based referrals. The investigators recently piloted MINDSET, an intervention that fills this gap. MINDSET is a proactive, population-based intervention that uses a mailed packet with tailored education about how drinking\u002Fsmoking relate to the Veteran's condition (heart conditions and\u002For diabetes), followed by a brief motivational call. The investigators will test MINDSET's effectiveness versus usual primary care on outcomes including intention to change and substance use and evaluate the relationships between these and other variables over time.",[30,339],"Alcohol-Related Disorders",[341,61,342,343,344,345,346],"Chronic Disease","Drinking, Alcohol","Cardiovascular Risk","Health Behavior","Medicine, Behavioral","telehealth","2025-12-23",{"date":349,"type":40},"2025-12-31",{"date":351,"type":40},"2025-10-01",{"date":353,"type":23},"2029-06-30",{"name":355,"class":356},"VA Office of Research and Development","FED",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":55,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":373,"locationsCount":4},"100617818","a-study-to-assess-nicotine-uptake-from-electronic-nicotine-delivery-systems-100617818","NCT07323563","A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems","A Randomized, Crossover, Confinement Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n* Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n* Positive urine cotinine test at Screening.\n* Smokes combustible, filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n* Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n* Participants must meet one (a or b) of the following tobacco use conditions:\n\n  1. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of the Principal Investigator (PI).\n  2. Dual user of cigarettes and ENDS who self-reports:\n\n  i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence more than 30 days prior to Screening due to illness, quit attempt, or clinical study participation will be allowed at the discretion of the PI and ii. Using a nicotine-containing ENDS (cartridge or tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco and modern oral nicotine products) on no more than 1 day per week will not be excluded from study participation.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n* Willing to use only UB cigarette and assigned test ENDS IPs during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n* Females must be willing to use a form of contraception acceptable to an Investigator, including abstinence from heterosexual intercourse, from the time of signing informed consent until EOS. Examples of acceptable means of birth control include, but are not limited to:\n\n  1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n  2. Physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n  3. Non-hormone-releasing intrauterine devices (IUDs) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n  4. Vasectomized partner;\n  5. Post-menopausal and not on hormone replacement therapy; or\n  6. Sexual abstinence, defined as refraining from intercourse, when this is in line with the preferred and usual lifestyle of the participant.\n* Males must use an acceptable method of birth control from Day 1 Check-in until EOS, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for 5 minutes at Screening and at Check-in Day 1.\n* Weight of ≤ 110 pounds (≤ 50.0 kg) and body mass index of \\> 40.0 kg\u002Fm2 at Screening.\n* Hemoglobin level is \\\u003C 12.5 for females or \\\u003C 13.0 for males g\u002FdL at Screening.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco- or nicotinecontaining products other than cigarettes or ENDS within the last 6 months prior to Screening.\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), glucagon-like peptide-1 (GLP-1) agonists (e.g., Wegovy®, Mounjaro®, Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n* History or presence of bleeding or clotting disorders.\n* Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n* Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and Check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n\n• Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and Check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n\n* Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n* Females who have a positive pregnancy test at Screening or Check-in on Day 1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n* Has positive urine drug screen or alcohol test (urine or breath) at Screening or at Checkin to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at Check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an Investigator.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n* Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by the PI, or has a positive alcohol test at Screening or Checkin on Day 1.\n* Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n* Individuals or their family members who have ongoing litigation with tobacco company(ies).\n* Determined by the PI to be inappropriate for this study.",{"count":97,"type":23},[26],"This will be an open-label, randomized, single-site, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters and overall product liking (OPL) following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult combustible cigarette smokers and smokers who also use ENDS products.",[61,101,65,30],"2025-12-22",{"date":318,"type":40},{"date":371,"type":23},"2026-03-15",{"date":273,"type":23},{"name":110,"class":111},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":55,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100617814","abuse-liability-for-eight-electronic-nicotine-products-100617814","NCT07323511","Abuse Liability for Eight Electronic Nicotine Products","An Open-Label, Randomized, 8-way Crossover Study to Assess Elements of Abuse Liability of Electronic Nicotine Delivery System Products in Adult Smokers","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n* Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n* Positive (≥200 ng\u002Fml) urine cotinine test at Screening.\n* Smokes only combustible filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n* Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n* Participants must meet one (a or b) of the following tobacco use conditions:\n\n  1. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of the Principal Investigator (PI).\n  2. Dual user of cigarettes and ENDS who self-reports:\n\n  i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the PI and ii. Using a nicotine-containing ENDS (cartridge or a tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco, and modern oral nicotine products) on no more than one day per week will not be excluded from study participation.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n* Willing to use only UB cigarette, ENDS IPs, and nicotine gum during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n* Females must be willing to use a form of contraception acceptable to the PI from the time of signing informed consent until End-of-Study.\n* Males must use an acceptable method of birth control from Day 1 \"check-in\" until the end of the study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening and at check-in Day 1.\n* Weight of ≤ 110 pounds at Screening.\n* Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C13.0 g\u002FdL for males at Screening.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco products other than cigarettes or ENDS within the last 6 months prior to screening.\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n* History or presence of bleeding or clotting disorders.\n* Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n* Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n\n• Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n\n* Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n* Females who have a positive pregnancy test at Screening or check-in on Day 1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n* A positive drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or Day 1.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n* Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by the PI, or has a positive alcohol test at Screening or check-in on Day 1.\n* Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n* Individuals or their family members that have ongoing litigation with tobacco company(ies).\n* Determined by the PI to be inappropriate for this study.",{"count":382,"type":23},70,[26],"This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]), and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.",[61,101,65,30],{"date":318,"type":40},{"date":388,"type":23},"2026-02-15",{"date":390,"type":23},"2026-09-15",{"name":110,"class":111},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":55,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":399,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":48},"100603153","abuse-liability-for-five-modern-oral-nicotine-products-100603153","NCT07132814","Abuse Liability for Five Modern Oral Nicotine Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Five Modern Oral Nicotine Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco.\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Smokers who also use ST products (e.g., moist snuff, snus, modern oral), and have used ST within 30 days prior to screening, will be enrolled.\n6. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n8. Positive urine cotinine test (e.g., \\>200 ng\u002FmL) via dipstick at Screening.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" .\n10. Willing to use the UB cigarette, Study IPs, and Nicorette® nicotine gum (Arm 2 only) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n    4. vasectomized partner; or\n    5. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system (e.g., Vuse Alto, JUUL) or tobacco heating device (e.g., iQOS) within the last 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day -1.\n10. Weight of ≤ 50.0 kg at screening or at check-in.\n11. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n12. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n13. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day -1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n14. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n15. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to signing the informed consent.\n16. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n17. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n18. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n19. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day -1.\n20. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day -1.\n21. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n22. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n23. Drinks more than 21 servings of alcoholic beverages per week.\n24. Determined by an investigator to be inappropriate for this study.",{"count":97,"type":23},[26],"This is a two-site, open-label, randomized, 4-way (2 arm) cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of the study investigational products (IPs) by generally healthy smokers",[61,101,65,30],{"date":404,"type":40},"2025-12-30",{"date":406,"type":40},"2025-12-15",{"date":273,"type":23},{"name":110,"class":111},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":55,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100613484","abuse-liability-for-four-heated-tobacco-product-htp-consumables-and-two-htp-devices-100613484","NCT07267195","Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices","An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n* Smokes combustible, filtered, non-menthol (Arm 1 only) or menthol cigarettes (Arm 2 only), 83 mm to 100 mm in length as primary source of tobacco. Smokers who also use other tobacco products (e.g., ENDS, smokeless tobacco, HTPs) will not be excluded from study participation,\n* Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the PI.\n* Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n* Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day -1).\n* Positive urine cotinine test (e.g., \\>200 ng\u002FmL) via dipstick at Screening.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991).\n* Willing to use the UB cigarette, Study IPs, and Nicorette® nicotine gum during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n* Females must be willing to use a form of contraception acceptable to the PI from the time of signing the ICF until End-of-Study.\n* Examples of acceptable means of birth control are, but not limited to:\n\n  * Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral\n  * oophorectomy, bilateral salpingectomy);\n  * physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with\n  * spermicide;\n  * non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs\n  * (e.g., Mirena or Kyleena);\n  * vasectomized partner; or\n  * post-menopausal and not on hormone replacement therapy\n  * abstinence.\n* Males must use an acceptable method of birth control from Day -1 \"check-in\" until the End-of-Study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to an in-clinic confinement of 10 days (9 nights).\n* BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening).\n\nExclusion Criteria:\n\n* Individuals or their family members that have ongoing litigation with tobacco company(ies).\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* History or presence of bleeding or clotting disorders.\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Systolic BP of \\> 160 mmHg or a diastolic BP of \\> 95 mmHg, measured after being seated for 5 minutes at Screening or at check-in Day -1.\n* Weight of \\> 50.0 kg at Screening.\n* Hemoglobin level is \\> 12.5 g\u002FdL for females or \\> 13.0 g\u002FdL for males at Screening.\n* Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Has positive urine drug screen or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day -1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of the PI.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Mounjaro®, Ozempic®, Wegovy®), or lobelia extract within (≤) 30 days prior to signing the informed consent.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n* Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n* Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n* Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day -1.\n* Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day -1.\n* Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n* Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n* Drinks more than 21 servings of alcoholic beverages per week.\n* Determined by the PI to be inappropriate for this study.",{"count":97,"type":23},[26],"This is a single-site, open-label, randomized, 8-way crossover study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]), during and following ad libitum use of the study investigational products (IPs) by generally healthy adult smokers.",[61,101,65,30],"2025-12-08",{"date":422,"type":40},"2025-12-16",{"date":424,"type":23},"2026-01",{"date":426,"type":23},"2026-12",{"name":110,"class":111},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":435,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":48},"100611130","buteyko-breathing-and-approach-of-smoking-hygiene-effects-on-dysfucntion-of-eustachian-tube-and-lung-functions-100611130","NCT07236580","Buteyko Breathing and Approach of Smoking Hygiene: Effects on Dysfucntion of Eustachian Tube and Lung Functions","Is There Efficacy of Adding Buteyko Breathing to Approach of Smoking Hygiene on Dysfucntion of Eustachian Tube and Lung Functions in Adolescnets Who Are Passively Exposed to Tobacco Smoke?","Inclusion Criteria:\n\n* Dysfucntion of Eustachian Tube (obstructive chronic form)\n* adolescents with passive tobacco exposure from smoking parent or household member\n* adolscent participants whose parents approve the participation\n\nExclusion Criteria:\n\n* cardiac problem\n* chest disease\n* renal\u002Fhepatic disease","13 Years","17 Years",{"count":97,"type":23},[26],"adolescents are usually exposed to tobacco smoke passively. this can reduce their lung functions and negatively impact functions of Eustachian tube. The solution is to lower rates to tobacco exposure and use the support of Buteyko Breathing",[30,441],"Eustachian Tube Dysfunction","2025-11-15",{"date":136,"type":40},{"date":445,"type":40},"2025-09-15",{"date":106,"type":23},{"name":448,"class":47},"Cairo University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":458,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":482},"100569396","a-study-evaluating-the-use-of-an-indoor-air-quality-monitor-to-promote-a-smoke-free-home-100569396","NCT06693700","A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home","Freedom to Breathe: Pilot Study Towards Achieving Environmental Justice for Cancer Patients and Their Families","Inclusion Criteria:\n\n* Adult (aged \\>18 years) MSK patients as per the EHR\n* Has been referred and enrolled in the MSK TTP and completed the initial counseling session as per the TTP clinical database\n* Reports current (within the past 30 days) tobacco use (i.e., cigarettes and\u002For any other tobacco products) as per the TTP Intake form\n* Must be English-speaking in the EHR\n* Must be reachable by phone as per self-report\n* Must have Wi-Fi available at home as per self-report\n\nExclusion Criteria:\n\n* Patient reports that no smoking is allowed, by them or anyone else, in the home as per the TTP intake form and\u002For per self-report",{"count":457,"type":23},10,[26],"The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.",[61,125,127,461,101,63,62,462,65,30],"Smoking Habit","Smoking (Tobacco) Addiction",[69,464,465,466,467,71,70,468,469,470,471,472,473,77],"smoking cessation","smoking reduction","smoking habit","smoking behaviors","smoking (tobacco) addiction","tobacco use","tobacco smoking","air quality","indoor air quality monitoring devices","24-260","2025-10-21",{"date":476,"type":40},"2025-10-22",{"date":478,"type":40},"2024-11-14",{"date":480,"type":23},"2027-11-14",{"name":77,"class":47},8,{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":48},"100523626","phase-4-smoking-cessation-program-in-the-construction-sector-100523626","NCT06098144","Smoking Cessation Program in the Construction Sector","Expanding the Role of the Safety Manager to Implement a Workplace Smoking Cessation Program in the Construction Sector","Inclusion Criteria:\n\nCompany leaders:\n\n* ≥ 18 years\n* Involved in decision making\n* Willing to participate in the implementation development and evaluation\n\nSafety Managers:\n\n\\- ≥ 18 years Self-identified as a safety manager or superintendent Have no plans to leave the company in the next year Speak either English or Spanish Non-cigarette smoker Willing to receive training in smoking cessation treatment Willing to deliver the smoking cessation treatment to workers\n\nConstruction Workers:\n\n* Be a construction worker\n* ≥ 18 years\n* Have smoked on average 5 or more cigarettes daily for the past year\n* Willing to make a serious quit attempt in the next 30 days\n* Willing to receive treatment from the Florida Tobacco Quitline.\n* Planning to stay in the company for the next 6 months\n* Own a telephone and plan to keep it active for the next 12 months\n\nExclusion Criteria:\n\nSafety Managers:\n\n\\- Current cigarette smoker",{"count":491,"type":23},608,[211],"The main objective of this study is to identify the optimal adaptive smoking cessation program for the construction sector in terms of effectiveness, cost-effectiveness, and potential implementation.",[125,126,30],"2025-08-26",{"date":497,"type":40},"2025-09-03",{"date":499,"type":40},"2024-04-10",{"date":501,"type":23},"2027-02-28",{"name":503,"class":47},"University of Miami",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":18,"minAge":94,"maxAge":512,"enrollmentInfo":513,"targetDuration":4,"studyType":24,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":48},"100593091","phase-1-effects-of-cannabidiol-on-stress-and-nicotine-withdrawal-100593091","NCT07001930","Effects of Cannabidiol on Stress and Nicotine Withdrawal","Pharmacological Effects of Cannabidiol on Responses to Stress and Nicotine Withdrawal","CREWS","Inclusion Criteria:\n\n1. Healthy non-treatment seeking adults aged 21-70 (inclusive).\n2. Use of \\> 5 cigarettes per day for \\> 2 years. (Use of other tobacco\u002Fnicotine products in addition to cigarettes will be acceptable).\n3. Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level \\> 8 ppm.\n4. Alcohol Use: \\\u003C 2 drinks\u002Fday on average (\\\u003C 14 drinks\u002Fweek).\n5. Sleep schedule: No graveyard or third shift work (i.e., participants must report a normal nighttime sleep schedule).\n6. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration.\n\nExclusion Criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis\n4. Positive breath alcohol test (\\>.01 g\u002F210L) at study admission\n5. Have a current physical or mental illness or takes a medication judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a resting heart rate \\>100, systolic blood pressure \\>160mmHg or \\\u003C100mmHg, or diastolic blood pressure \\>100mmHg or \\\u003C50mmHg at screening.\n7. Have cold intolerance or a medical condition that might be exacerbated by exposure to cold (e.g. Reynaud's, peripheral neuropathy, trigeminal neuralgia, poorly controlled\u002Funcontrolled hypothyroidism).\n8. Are currently pregnant, planning to become pregnant in the next three months, or are currently breastfeeding\n9. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina, Raynaud's).\n10. Have a history of and\u002For current liver disease, or elevated serum liver transaminase (AST or ALT) above 3 x Upper Limit of Normal (ULN), or elevated bilirubin above 2 x ULN at screening.\n11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.","70 Years",{"count":514,"type":23},90,[310],"The purpose of this study is to examine the effect of doses of cannabidiol (CBD) during exposure to stress and nicotine withdrawal in nicotine users. The main objectives of the study include examining the effect CBD has on stress, tobacco dependence, tobacco withdrawal, and sex differences between these types of stress. Participants will be administered CBD and exposed to stress. Biological and subjective measures will be collected. Participants may be asked to stop use for 24 hours. Researchers will also investigate withdrawal effects between participants who have not smoked nicotine in 24 hours and those who have continued to smoke before each session.",[315,518,214,30],"Stress",[315,518,182,30],"2025-08-25",{"date":522,"type":40},"2025-09-02",{"date":520,"type":40},{"date":525,"type":23},"2029-09-01",{"name":324,"class":47},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":24,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":48},"100577440","phase-4-tdcs-plus-varenicline-for-smoking-cessation-100577440","NCT06798324","tDCS Plus Varenicline for Smoking Cessation","Using Non-Invasive Brain Stimulation (tDCS) as an Adjunct to Varenicline for the Treatment of Tobacco Dependence: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Be able to provide informed written consent\n* Stated willingness to comply with all study procedures\n* Age 18-85 years\n* Smoke ≥ 8 cigarettes per day (CPD)\n* Is seeking treatment for tobacco dependence\n* Willing to attend the required clinic appointments (Two consecutive weeks, Monday through Friday)\n* Otherwise healthy (i.e. not suffering from any major illness\u002Fcondition that would impact their participation in the study)\n\nExclusion Criteria:\n\n* Use of smoking cessation medication (e.g. buproprion, varenicline, NRT, cytisine) in the past 3 months\n* Current regular use of nicotine-containing products besides cigarettes (e.g. electronic cigarettes, etc.)\n* Unstable psychiatric illness that would adversely impact study participation and compliance (determined by the QI)\n* History of seizures\u002Fepilepsy\n* Lifetime history of concussions or head traumas\n* Current pregnancy or plans to become pregnant\n* Current pacemakers or implanted electrical devices\n* Current metal embedded in the skull\n* Presence of skin lesions, open wounds, or bruising at stimulation sites; or\n* Contraindications to varenicline use (e.g. pregnant\u002Fbreastfeeding, alcohol dependence, kidney disease\u002Frenal impairment, known hypersensitivity to varenicline)","85 Years",{"count":536,"type":23},160,[211],"The goal of this clinical trial is to determine if active transcranial direct current stimulation (tDCS) plus varenicline is an effective, safe and accessible treatment option for smoking cessation. The main questions this trial aims to answer are:\n\n1. Does active tDCS plus varenicline improve short-term and long-term smoking abstinence rates compared to sham tDCS plus varenicline?\n2. Are the safety profiles between active tDCS plus varenicline and sham tDCS plus varenicline different?\n\nThe tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.",[214,30,125,215,155,216],[61,155,125,216,541,542,543,544,545],"Brain Stimulation","Transcranial Direct Current Stimulation","Tobacco Cigarettes","tDCS","Varenicline","2025-08-07",{"date":548,"type":40},"2025-08-12",{"date":550,"type":40},"2025-03-10",{"date":552,"type":23},"2028-08-01",{"name":198,"class":47},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":24,"phases":564,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":48},"100583802","reach-through-equitable-implementation-in-utah-100583802","NCT06881069","Reach Through Equitable Implementation in Utah","Reach Through Equitable Implementation in Utah (REI-UT)","REI-UT","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Speak English or Spanish\n* Currently use tobacco\n* Live in a persistent poverty census tract\n* Present at participating clinics\n* Valid cell phone number in the electronic health record (EHR)\n* Electronic health records indicate they have not opted out of receiving text contact from the clinic\n\nExclusion Criteria:\n\n* Opt-out of study",{"count":563,"type":23},1560,[26],"The goal of this pragmatic, multilevel Type III Hybrid Effectiveness-Implementation trial is to increase the reach of existing evidence-based interventions (EBIs) for tobacco cessation and to mitigate the impact of adverse Social Drivers of Health (SDOH) among safety-net healthcare system patients who live in persistent poverty (PP) census tracts.\n\nAim 1: Test the ability of patient-level Conversational Agents (CA) \\& Patient Navigation (PN) dissemination strategies to increase the Reach (primary outcome) of evidence-based tobacco cessation treatment delivered via the Utah Tobacco and Nicotine Quit Services (Quit Services) among Community Health Center (CHC) patients who use tobacco and live in persistent poverty census tracts. Secondary analyses will examine the outcome of Reach of services for SDOH among these patients and will evaluate both 1) patient-level CA and PN dissemination strategies and 2) a clinic-level implementation strategy using a pre-post design.\n\nAim 2: Explore contextual factors (e.g., clinic size, patient composition, rurality, patient demographics) related to the Reach, Adoption, Implementation, and potential Maintenance of strategies.\n\nAim 3: Determine the cost-effectiveness of clinic and patient-level strategies based on Quit Services enrollment and service receipt for SDOH.\n\nThis trial implements a clinic-level implementation strategy, Ask-Advise-Connect (AAC), to address tobacco cessation and needs around social drivers of health for patients in all participating clinics. Eligible patients who are not enrolled in Quit Services four weeks after the clinical encounter, will receive text messages from a chatbot offering information and connections to the Quit Services and patient navigation support from a Community Health Worker.",[126,65,30,567,156],"Tobacco Chewing","2025-03-11",{"date":570,"type":40},"2025-03-18",{"date":572,"type":40},"2025-02-13",{"date":574,"type":23},"2028-01-30",{"name":576,"class":47},"University of Utah",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":48},"100529181","smoke-free-home-study-in-subsidized-housing-100529181","NCT06170437","Smoke-free Home Study in Subsidized Housing","Healthy Homes Study: A Protocol for a Place-based Smoke-free Home Intervention in Federally Subsidized Housing","Inclusion Criteria:\n\nEligible resident participants\n\n* Current smokers defined as:\n\n  * Smoked at least 100 cigarettes in lifetime\n  * Smoked daily in the past 7 days, and at least 5 cigarettes per day, verified by expired CO ≥ 5 parts per million \\[ppm\\] Smokerlyzer CO+ monitor),\n  * Smoke in their home\n* Expect to live in the subsidized housing site for at least 12 months\n* Age ≥ 18 years\n* Speak Chinese (Cantonese or Mandarin), English, Spanish, or Vietnamese\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Contraindication to any study-related procedures or assessment",{"count":585,"type":23},544,[26],"Comprehensive smoke-free policies have the potential to substantially reduce tobacco-related disparities among populations in subsidized housing. This study fills this gap by identifying approaches to increase the implementation of smoke-free policies in all types of subsidized housing by increasing the voluntary adoption of smoke-free homes and promoting access to smoking cessation services.",[156,30],"2025-02-20",{"date":591,"type":40},"2025-02-24",{"date":593,"type":40},"2024-07-12",{"date":595,"type":23},"2027-08-31",{"name":140,"class":47},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":604,"targetDuration":606,"studyType":58,"phases":4,"briefSummary":607,"conditions":608,"keywords":611,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":48},"100567825","inspire-respiratory-health-program-in-botucatu-so-paulo-brazil-100567825","NCT06673225","INSPIRE Respiratory Health Program in Botucatu, São Paulo, Brazil","Evaluation of the Implementation of the INSPIRE Respiratory Health Program: Integration of Early Diagnosis and Emergency Response for Respiratory Diseases in the City of Botucatu, São Paulo, Brazil","Inclusion Criteria:\n\n* Age equal to or greater than 18 years old;\n* Respiratory symptoms\n* History of active or passive smoking\n* Signing of informed consent form\n\nExclusion Criteria:\n\n* Difficulty understanding the issues addressed\n* Inability to contact by phone\n* Non-signing or withdrawal of informed consent",{"count":605,"type":23},2000,"5 Years","The goal of this observational study is to evaluate the implementation of the INSPIRE program and to plan actions for the preparation, coordination, monitoring, diagnosis, and treatment of respiratory diseases in the municipality of Botucatu. Methods: Individuals with respiratory symptoms from the municipality of Botucatu, aged 18 or older, will be invited to participate in the study, and socioeconomic data, as well as information on sex, gender, race, nutritional risk, frailty, tobacco exposure, and its derivatives, will be collected. For those with exposure, screening and treatment for respiratory diseases will be offered through assessment of pulmonary function, body composition, respiratory and peripheral muscle strength. Additionally, individuals over 40 years old with tobacco exposure equal to or greater than 30 pack-years will be offered low-dose chest CT screening for lung cancer. Expected results: To identify and assess vulnerable groups that face difficulties in accessing respiratory healthcare, as well as implement specific strategies for the treatment of respiratory diseases and tobacco control for these groups. To ensure equitable access to respiratory health for the entire population at risk due to smoking. Moreover, through proactive and reactive risk reduction actions implemented by the program, to intervene in distinct groups and other regions.",[609,610,30],"Community Health Services","Respiratory Disease",[612,613,614,615,186],"Primary care","Health promotion","Pulmonary function tests","Nicotine addiction",{"date":617,"type":40},"2024-11-04",{"date":619,"type":40},"2024-04-16",{"date":621,"type":23},"2029-12-01",{"name":623,"class":47},"UPECLIN HC FM Botucatu Unesp",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":24,"phases":634,"briefSummary":635,"conditions":636,"keywords":637,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":48},"100550746","brief-behavioural-economic-intervention-for-smoking-cessation-100550746","NCT06451081","Brief Behavioural Economic Intervention for Smoking Cessation","Building Capacity and Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2024: a Randomised Controlled Trial of a Brief Behavioural Economic Intervention","QTW2024","Inclusion Criteria:\n\n1. Hong Kong residents aged 18 years or above\n2. Smoke cigarette or heated tobacco product or e-cigarette daily in the past 3 months\n3. Exhaled carbon monoxide level ≥4 parts per million or a positive salivary cotinine test\n4. Able to communicate in and read Chinese\n5. Own a smartphone with a mobile instant messaging app installed\n\nExclusion Criteria:\n\n* Participating in another smoking cessation programme or using any smoking cessation drug or nicotine replacement therapy",{"count":633,"type":23},1017,[26],"The goal of this clinical trial is to test the effectiveness of brief behavioural economic intervention in promoting smoking cessation among smokers in the community.",[30],[638,639,640,641,642],"cessation","tobacco","behavioural economics","nudge","opt-out","2024-07-17",{"date":645,"type":40},"2024-07-19",{"date":647,"type":40},"2024-06-15",{"date":649,"type":23},"2025-05-31",{"name":651,"class":47},"The University of Hong Kong"]